Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Pergoveris Market Value Expansion And Long-Term Growth Outlook
The expansion seen in the historic period was driven by a greater number of gonadotropin deficiency diagnoses, the proliferation of assisted reproductive clinics, improved success rates associated with IVF treatments, the availability of recombinant hormone technologies, and heightened awareness around infertility.
The forecast period’s growth is driven by heightened demand for sophisticated IVF protocols, a stronger emphasis on precise hormone therapy, the broadening of fertility tourism, greater uptake of user-friendly injectable formats, and increased funding for reproductive biotechnology. Within this time frame, key developments encompass the growing utilization of recombinant hormone treatments, a surge in IVF and ART procedure requests, expanded application of injectable pen delivery systems, the rise of precisely regulated fertility therapies, and an intensified concentration on managing hormone deficiencies.
Download A Free Sample Report For Comprehensive Market Insights:
Pergoveris Market Growth Drivers And Industry Catalysts
The ongoing rise in infertility cases is anticipated to propel the pergoveris market forward. Infertility describes the inability to conceive, sustain a pregnancy, or carry it to full term. This condition is becoming more common due to delayed childbearing, lifestyle patterns, environmental pollutants, and a growing incidence of health issues such as polycystic ovary syndrome (PCOS) and endometriosis. Pergoveris assists infertility patients by boosting ovarian function via a blend of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), encouraging egg development in women with severe gonadotropin deficiency. As an example, in April 2023, the World Health Organization, an intergovernmental body based in Switzerland, reported that around 17.5% of the global adult population, or roughly 1 in 6 individuals, experiences infertility. Consequently, the growing prevalence of infertility is fueling expansion in the pergoveris market.
A higher uptake of IVF procedures is set to drive growth in the pergoveris market going ahead. IVF procedures are medical approaches that help individuals or couples achieve conception by fertilizing an egg with sperm outside the body and then placing the resulting embryo into the uterus. This method is being adopted more widely as people postpone parenthood for career, educational, or social reasons, leading to age-related fertility decreases and a stronger dependence on fertility therapies. Pergoveris is vital to this rising adoption by enabling controlled ovarian stimulation and enhancing pregnancy outcomes for those with low ovarian response. For instance, in June 2025, the Human Fertilisation & Embryology Authority, an independent fertility regulator in the UK, reported that in 2023, 52,400 patients underwent over 77,500 in vitro fertilization (IVF) cycles at licensed clinics in the UK. Egg freezing cycles grew from 4,700 in 2022 to 6,900 in 2023, making up 7% of all cycles. Hence, the increasing adoption of IVF procedures is propelling the pergoveris market forward.
Pergoveris Market Segmentation And Category Breakdown
The pergoveris market covered in this report is segmented –
1) By Formulation: Injectable Pen, Vial Formulation
2) By Indication: Anovulation, Assisted Reproductive Technology (ART) Procedures
3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Pergoveris Market Trends Influencing Long-Term Demand
Within the pergoveris market, major players are concentrating efforts on regulatory and access-driven innovations, including priority-review submissions through the FDA Commissioner’s National Priority Voucher (CNPV) program, with the aim of accelerating approval processes, broadening patient access, and making complex fertility therapies more affordable. Such a priority-review filing allows regulatory bodies to reduce the standard 10-to-12-month evaluation period to just one or two months, thereby enabling quicker availability of cutting-edge reproductive treatments while still upholding safety and efficacy standards. To illustrate, in October 2025, EMD Serono—the healthcare division of Merck KGaA, headquartered in Darmstadt, Germany—filed Pergoveris® under the FDA CNPV initiative. This therapy pairs recombinant human follicle-stimulating hormone (r-hFSH) with recombinant human luteinizing hormone (r-hLH) in a 2:1 ratio, and it is delivered via a pre-filled Redi-ject® pen that simplifies dosing, cuts down the number of injections, and improves the overall user experience. Pergoveris is engineered to mimic natural reproductive physiology, thereby fostering follicular growth and maturation within medically assisted reproduction cycles. Additionally, this program works in conjunction with public-private partnerships and direct-to-consumer access efforts, further enhancing affordability and widening treatment choices for women facing severe FSH/LH deficiency.
Pergoveris Market Competitive Analysis Of Major Industry Participants
Major companies operating in the pergoveris market are Merck KGaA
Access The Complete Pergoveris Market Report:
Pergoveris Market Regional Analysis And Leading Geography
Europe was the largest region in the pergoveris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pergoveris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model